Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
RLMD.US
id: 705

Relmada (RLMD) Case

  • Relmada (RLMD) revealed that the RELIANCE III trial did not achieve its primary endpoint.
  • $RLMD fell nearly 80% & lost over $700 million of its market cap.
  • Investors may have reasons to suspect Renada & its Leaders of misleading which could lead to investment losses.
On October 13, 2022, Relmada (RLMD) revealed that the RELIANCE III trial did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to the placebo on Day 28, as measured by the Mongomery-Asberg Depression Rating Scale (MADRS).

Specifically, the REL-1017 treatment showed a MADRS reduction of 14.8 points on Day 28 versus 13.9 points for the placebo, a higher-than-expected placebo response. Relmada described that "paradoxical results were observed in certain study sites, where placebo dramatically outperformed REL-1017."

On this news, $RLMD fell nearly 80% and lost over $700 million of its market cap, dramatically damaging investors.

Taking all facts and market reaction into account, Investors may have reasons to suspect Renada and its Leaders of misleading which could lead to investment losses.
Case Status
Attorney Investigation
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
13 October 2022
Collecting participants…

Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead p...

    Ticker
    RLMD.US
    ISIN
    US75955J4022
    CIK
    1553643
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134